Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127.
Montoya S, Bourcier J, Noviski M, Lu H, Thompson MC, Chirino A, Jahn J, Sondhi AK, Gajewski S, Tan YSM, Yung S, Urban A, Wang E, Han C, Mi X, Kim WJ, Sievers Q, Auger P, Bousquet H, Brathaban N, Bravo B, Gessner M, Guiducci C, Iuliano JN, Kane T, Mukerji R, Reddy PJ, Powers J, Sanchez Garcia de Los Rios M, Ye J, Barrientos Risso C, Tsai D, Pardo G, Notti RQ, Pardo A, Affer M, Nawaratne V, Totiger TM, Pena-Velasquez C, Rhodes JM, Zelenetz AD, Alencar A, Roeker LE, Mehta S, Garippa R, Linley A, Soni RK, Skånland SS, Brown RJ, Mato AR, Hansen GM, Abdel-Wahab O, Taylor J. Montoya S, et al. Among authors: totiger tm. Science. 2024 Feb 2;383(6682):eadi5798. doi: 10.1126/science.adi5798. Epub 2024 Feb 2. Science. 2024. PMID: 38301010 Free PMC article.
E7820, an anti-cancer sulfonamide, degrades RBM39 in patients with splicing factor mutant myeloid malignancies: a phase II clinical trial.
Bewersdorf JP, Stahl M, Taylor J, Mi X, Chandhok NS, Watts J, Derkach A, Wysocki M, Lu SX, Bourcier J, Hogg SJ, Rahman J, Chaudhry S, Totiger TM, Abdel-Wahab O, Stein EM. Bewersdorf JP, et al. Among authors: totiger tm. Leukemia. 2023 Dec;37(12):2512-2516. doi: 10.1038/s41375-023-02050-4. Epub 2023 Oct 9. Leukemia. 2023. PMID: 37814121 Free PMC article. Clinical Trial. No abstract available.
Targeted Therapy Development in Acute Myeloid Leukemia.
Totiger TM, Ghoshal A, Zabroski J, Sondhi A, Bucha S, Jahn J, Feng Y, Taylor J. Totiger TM, et al. Biomedicines. 2023 Feb 20;11(2):641. doi: 10.3390/biomedicines11020641. Biomedicines. 2023. PMID: 36831175 Free PMC article. Review.
Tracking the evolution of therapy-related myeloid neoplasms using chemotherapy signatures.
Diamond B, Ziccheddu B, Maclachlan K, Taylor J, Boyle E, Ossa JA, Jahn J, Affer M, Totiger TM, Coffey D, Chandhok N, Watts J, Cimmino L, Lu SX, Bolli N, Bolton K, Landau H, Park JH, Ganesh K, McPherson A, Sekeres MA, Lesokhin A, Chung DJ, Zhang Y, Ho C, Roshal M, Tyner J, Nimer S, Papaemmanuil E, Usmani S, Morgan G, Landgren O, Maura F. Diamond B, et al. Among authors: totiger tm. Blood. 2023 May 11;141(19):2359-2371. doi: 10.1182/blood.2022018244. Blood. 2023. PMID: 36626250 Free PMC article.
Combination venetoclax and selinexor effective in relapsed refractory multiple myeloma with translocation t(11;14).
Nguyen N, Chaudhry S, Totiger TM, Diaz R, Roberts E, Montoya S, Pardo G, Pardo A, Afaghani J, Affer M, Jahn J, Bradley T, Maura F, Kazandjian D, Bilbao D, Chapman J, Landgren O, Hoffman J, Taylor J. Nguyen N, et al. Among authors: totiger tm. NPJ Precis Oncol. 2022 Oct 19;6(1):73. doi: 10.1038/s41698-022-00315-2. NPJ Precis Oncol. 2022. PMID: 36261486 Free PMC article.
Urolithin A attenuates severity of chronic pancreatitis associated with continued alcohol intake by inhibiting PI3K/AKT/mTOR signaling.
Mehra S, Srinivasan S, Singh S, Zhou Z, Garrido V, Silva IC, Totiger TM, Dosch AR, Dai X, Dawra RK, Jala VR, Shi C, Datta J, VanSaun M, Merchant N, Nagathihalli N. Mehra S, et al. Among authors: totiger tm. Am J Physiol Gastrointest Liver Physiol. 2022 Oct 1;323(4):G375-G386. doi: 10.1152/ajpgi.00159.2022. Epub 2022 Sep 13. Am J Physiol Gastrointest Liver Physiol. 2022. PMID: 36098401 Free PMC article.
Mechanisms of Resistance to Noncovalent Bruton's Tyrosine Kinase Inhibitors.
Wang E, Mi X, Thompson MC, Montoya S, Notti RQ, Afaghani J, Durham BH, Penson A, Witkowski MT, Lu SX, Bourcier J, Hogg SJ, Erickson C, Cui D, Cho H, Singer M, Totiger TM, Chaudhry S, Geyer M, Alencar A, Linley AJ, Palomba ML, Coombs CC, Park JH, Zelenetz A, Roeker L, Rosendahl M, Tsai DE, Ebata K, Brandhuber B, Hyman DM, Aifantis I, Mato A, Taylor J, Abdel-Wahab O. Wang E, et al. Among authors: totiger tm. N Engl J Med. 2022 Feb 24;386(8):735-743. doi: 10.1056/NEJMoa2114110. N Engl J Med. 2022. PMID: 35196427 Free PMC article.
15 results